QNTM · Quantum Biopharma Ltd. · Metrics
Market Cap
$9.13M
Shares
6.43M
Volume · Nov 19
78.98K
Avg daily vol (3M)
149.43K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
QNTM metrics
47 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$1.42
Market cap
$9.13M
Price action
23 metricsPrice change (1W)
-20.2%
Price change (30D)
-40.8%
Price change (3M)
-58.7%
Price change (6M)
-81.8%
Price change (YTD)
-80.5%
Price change (1Y)
-77.5%
Trailing year
Price change (5Y)
—
52-week high
$11.41
52-week low
$1.42
Change from 52-week high
-87.6%
Change from 52-week low
+0.0%
Annualized volatility
142.2%
Annualized volatility (3M)
76.6%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
24.3
Price vs SMA 50
-48.3%
Price vs SMA 200
-60.8%
Avg volume (3M)
149,425
Relative volume
0.5
Average dollar volume
$455,859
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
6.43M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 129.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11.19M
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-99.2%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
—
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.7
Interest coverage
-190.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.56M
Total assets
$17.33M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$6.56M
Capital expenditures (TTM)
—
R&D (TTM)
$1.48M
SG&A (TTM)
—
Stock compensation (TTM)
$2.34M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
28
13F filer change QoQ
+2
Institutional ownership
8.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+32.2%
Holder tenure
7.7
Price vs estimated holder cost
-37.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
6.8%
Latest settlement · 4.5 days to cover
Days to cover
4.5d
Short-squeeze score
54 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1771885
CUSIP
74764Y205
13F (30d)
28 filings
26 filers
Visit website
Investor relations